VALSARTAN Drug Patent Profile
✉ Email this page to a colleague
When do Valsartan patents expire, and when can generic versions of Valsartan launch?
Valsartan is a drug marketed by Novitium Pharma, Alembic, Alkem Labs Ltd, Amneal Pharms, Aurobindo Pharma Ltd, Dr Reddys, Hetero Labs Ltd V, Ivax Pharms, Jubilant Generics, Lupin Ltd, Macleods Pharms Ltd, Mylan, Ohm Labs Inc, Prinston Inc, Sciegen Pharms Inc, Square Pharms, Torrent, Unichem, Watson Labs Inc, Zenara, Zydus Lifesciences, Apotex Inc, Mylan Pharms Inc, and Watson Labs Teva. and is included in thirty-one NDAs.
The generic ingredient in VALSARTAN is hydrochlorothiazide; valsartan. There are thirty-two drug master file entries for this compound. Nineteen suppliers are listed for this compound. Additional details are available on the hydrochlorothiazide; valsartan profile page.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for VALSARTAN?
- What are the global sales for VALSARTAN?
- What is Average Wholesale Price for VALSARTAN?
Summary for VALSARTAN
| US Patents: | 0 |
| Applicants: | 24 |
| NDAs: | 31 |
| Finished Product Suppliers / Packagers: | 33 |
| Raw Ingredient (Bulk) Api Vendors: | 152 |
| Clinical Trials: | 385 |
| Patent Applications: | 5,185 |
| Drug Prices: | Drug price information for VALSARTAN |
| Drug Sales Revenues: | Drug sales revenues for VALSARTAN |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for VALSARTAN |
| What excipients (inactive ingredients) are in VALSARTAN? | VALSARTAN excipients list |
| DailyMed Link: | VALSARTAN at DailyMed |
Recent Clinical Trials for VALSARTAN
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| International Bio service | Phase 1 |
| Dr. Reddy's Laboratories (Thailand) Limited | Phase 1 |
| Unidade de Investigação e Desenvolvimento Cardiovascular (UnIC) | Phase 4 |
Pharmacology for VALSARTAN
| Drug Class | Angiotensin 2 Receptor Blocker |
| Mechanism of Action | Angiotensin 2 Receptor Antagonists |
Medical Subject Heading (MeSH) Categories for VALSARTAN
Anatomical Therapeutic Chemical (ATC) Classes for VALSARTAN
US Patents and Regulatory Information for VALSARTAN
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Watson Labs Inc | VALSARTAN | valsartan | TABLET;ORAL | 090642-003 | Jan 5, 2015 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Aurobindo Pharma Ltd | VALSARTAN AND HYDROCHLOROTHIAZIDE | hydrochlorothiazide; valsartan | TABLET;ORAL | 202519-005 | Mar 21, 2013 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Macleods Pharms Ltd | VALSARTAN | valsartan | TABLET;ORAL | 202696-004 | Sep 16, 2016 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Jubilant Generics | VALSARTAN | valsartan | TABLET;ORAL | 203536-003 | Jan 5, 2015 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Alembic | VALSARTAN AND HYDROCHLOROTHIAZIDE | hydrochlorothiazide; valsartan | TABLET;ORAL | 201662-005 | Mar 21, 2013 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Mylan Pharms Inc | VALSARTAN AND HYDROCHLOROTHIAZIDE | hydrochlorothiazide; valsartan | TABLET;ORAL | 078020-004 | Sep 21, 2012 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
